DT CAPITAL (00356) released its annual performance, with a net profit attributable to shareholders of HKD 2.59 million, reversing from a loss to a profit on a year-on-year basis.
Dingli Capital (00356) released its annual results for the year ending December 31, 2025. The group achieved revenue of HK$1.4344 million, a decrease of 34.69% year-on-year. The company's equity holders' profit for the year was HK$2.0259 million, compared to a loss of HK$12.0144 million in the same period last year. Earnings per share for the year were HK$0.0007.
DT CAPITAL (00356) announced its annual performance for the year ended December 31, 2025. The group achieved a revenue of HK$1.4344 million, a decrease of 34.69% compared to the previous year. The profit attributable to equity holders of the company for the year was HK$2.0259 million, compared to a loss of HK$12.0144 million in the same period last year. Earnings per share for the year were HK$0.0007 on a basic and diluted basis.
Compared to 2024, the profit for the reporting period was mainly attributable to fair value gains on financial assets recognized in profit or loss of approximately HK$8.87 million (compared to a loss of approximately HK$6.17 million in 2024). Additionally, there were no bank interest expenses in 2024 and 2025.
Related Articles

US Stock Market Move | HSBC Holdings (HSBC.US) fell more than 2% amid reports of plans to cut 20,000 jobs over the next few years.

Service business cooling can't hide strong hardware performance! Morgan Stanley: Apple Inc. (AAPL.US) iPhone production increases significantly, shipments may exceed market expectations.

IMMUNOTECH-B (06978) released its annual performance report, with a net loss attributable to shareholders of 231 million yuan, an increase of 23.47% year-on-year.
US Stock Market Move | HSBC Holdings (HSBC.US) fell more than 2% amid reports of plans to cut 20,000 jobs over the next few years.

Service business cooling can't hide strong hardware performance! Morgan Stanley: Apple Inc. (AAPL.US) iPhone production increases significantly, shipments may exceed market expectations.

IMMUNOTECH-B (06978) released its annual performance report, with a net loss attributable to shareholders of 231 million yuan, an increase of 23.47% year-on-year.

RECOMMEND

State Reform Fund And Three Major Banks Backstop Voyah As It Secures Hong Kong’s First Auto IPO This Year
20/03/2026

Hong Kong IPO Irregularities Surface As Corner Placements And Retail Losses Emerge, Haizhi Technology Implicated
20/03/2026

Gold And Silver Experience Sharp Sell‑Off As Global Rate‑Hike Expectations Intensify
20/03/2026


